CJC-1295 and Ipamorelin: What the Research Says
CJC-1295 and ipamorelin are two of the most-discussed growth-hormone peptides in research circles, and they’re frequently studied together. This overview explains what each one is, why they’re often paired, and what the research literature describes — strictly for educational and research context.
Two different jobs
Both compounds influence the body’s own growth-hormone (GH) pathways, but through different mechanisms:
- CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Its defining feature is a modification (often called drug-affinity-complex technology) that dramatically extends its half-life — from minutes to potentially days — so it provides a longer, steadier signal.
- Ipamorelin is a pentapeptide and a growth-hormone secretagogue. It works on a separate receptor (the ghrelin/GH-secretagogue receptor) and is studied for being highly selective — in research it shows GH release with minimal impact on cortisol, prolactin, or other hormones.
Why they’re studied together
The interest in pairing them comes down to complementary mechanisms. CJC-1295 acts like a sustained GHRH signal, while ipamorelin provides a cleaner, pulse-style secretagogue signal on a different pathway. Researchers explore the combination because the two pathways are additive in models — the GHRH analog and the secretagogue together are studied for a more pronounced effect than either alone. This is why “CJC-1295 + ipamorelin” is one of the most common search pairings in the peptide space.
What the evidence base looks like
It’s worth being precise here. Both compounds sit in an early evidence tier — roughly Phase 1–2 / limited human data — rather than having large, completed clinical programs behind them. Much of the published work is preclinical or early-stage. For researchers, that’s exactly the point: these are active areas of investigation, not settled science, and they should be approached as research compounds.
Handling and preparation
Like most peptides, CJC-1295 and ipamorelin are supplied as a lyophilised (freeze-dried) powder. They’re kept cold and protected from light, then reconstituted with bacteriostatic water for laboratory work. If you’re new to that process, our separate reconstitution guide and the on-site peptide calculator walk through preparing a solution and calculating concentration. Each batch we carry ships with a per-batch Certificate of Analysis so identity and purity can be verified.
Important context
This article summarises published research for educational purposes only. Both peptides are supplied strictly for laboratory and research use only — not for human or veterinary use, consumption, or injection. Nothing here is medical advice, a recommendation, or a dosing protocol. The mechanisms described are research findings, not approved claims, and researchers are responsible for safe handling and compliance with applicable laws.
The bottom line
CJC-1295 is a long-acting GHRH analog; ipamorelin is a selective GH secretagogue on a separate receptor. They’re studied together because their mechanisms complement each other, which is why the pairing draws so much research interest. As with everything we carry, both come with full batch documentation and a verifiable COA.
CJC-1295 with vs without DAC
A key distinction in CJC-1295 research is the presence or absence of DAC (drug-affinity-complex) technology. The DAC modification binds to albumin and dramatically extends half-life to several days, producing a sustained signal; the non-DAC form (sometimes called modified GRF 1-29) is shorter-acting and studied for a more pulse-like profile. The version chosen shapes the entire research design.
Why frequency matters in research
Because the two forms differ so much in half-life, research models treat them differently — long-acting DAC forms are studied with infrequent administration, while shorter forms are examined for tighter, more physiological pulsatility. This is one reason the CJC-1295 and ipamorelin pairing is studied so closely.
Related growth-hormone research
Researchers comparing GH approaches often look at CJC-1295 alongside recombinant growth hormone itself — see our HGH 191AA overview — and the broader Tesamorelin GHRH-analog research.
Research use only. Educational content, not medical advice.